Overview

Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies against CD46 for the treatment of late-stage multiple myeloma and late-stage prostate cancer and other indications. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D. The Company’s investors include Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners, Vivo Capital, the Myeloma Investment Fund, the venture philanthropy fund of the Multiple Myeloma Research Foundation, and Fulcrum 2020, LLC, which shares a portion of its profits with the Prostate Cancer Foundation (PCF) to fund future research.